The downgrade from Outperform to Market Perform by a reputable analyst like Mani Foroohar suggests a less favorable outlook for AlloVir's stock, which could lead to a decrease in investor confidence and a potential drop in the stock price in the short term. The announcement of a $1 price target, presumably below the current trading price, further supports the likelihood of a negative impact on the stock price.